Evaluation of a Combination of Plants in Anxiety-related Sleep Disorders: Randomized Trial Versus Placebo

Inclusion criteria

• Woman or man, aged of 18 to 65 years;
• In good general health as evidenced by medical history and physical examination;
• Having at least 3 episodes of sleep disorders per week including one or more of the following:

• difficulty falling asleep or
• difficulty staying asleep or
• poor quality sleep
• Waking up earlier than desired
• The insufficient sleep duration and quality is coupled with a feeling of general fatigue;
• Sleep disorder last for more than 1 month;
• Presenting moderate to severe sleep disorder in the past month (ISI ≥ 15);
• With anxiety resulting in a HAM-A score > 8 and < 25;
• For women of childbearing age (women of childbearing potential, pre-menopausal or having postmenopausal amenorrhea of less than 12 months, and women who have not undergone surgical sterilization):

• Negative blood pregnancy test
• Acceptance to use an effective method of contraception, established for at least 1 month, and throughout the duration of the study;
• Fluent French speaking;
• Provision of signed and dated informed consent form;
• Stated willingness to comply with all study procedures and availability for the duration of the study.

Exclusion criteria

• A score > 10 on the ESS scale (that would correspond to serious hypersomnia);
• Sleep disorders secondary to another health problem (sleep apnea syndrome, narcolepsy-cataplexy, idiopathic hypersomnia, restless legs syndrome, chronic pain syndrome, ...) or an environmental factor (noise, light ...) or socio-professional (shift work, young child at home, people who are often jet lagged,… );
• Severe psychiatric disorder or disease within 6 months before inclusion (depression, bipolar disorder, severe anxiety, psychosis, schizophrenic disorders, dementia,…) or a severe neurologic trouble (Alzheimer's, autism, Parkinson's disease, …);
• Subjects presenting severe gastro-intestinal, hepatic, respiratory, kidney or cardiovascular disorder or severe infection (e.g. HIV, hepatitis, …);
• Acute or chronic somatic pathologies which can interfere with sleep: kidney cancer, etc.;
• Subjects with pre-menstrual syndrome or myasthenia gravis;
• Subjects who drink more than 2 glasses of alcohol per day (> 20g of alcohol per day) or with exaggerated consumption of theine (≥ 1l per day) and caffeine-rich (≥ 800ml per day) beverages and energy drink (≥ 330ml per day);
• Smoker;
• Subject consuming drugs and/or with historical drug addiction;
• Under psychotropic treatment within the last month before screening (neuroleptic, anxiolytic, antidepressant, hypnotic, sedative, …) or under current medication treatment which may alter the waking state (for example: cortisone, dopamine, amphetamine, antihistamines, beta-blockers, certain cough syrups, .…);
• Volunteer with suicidal risk according to the investigator;
• Under phytotherapy treatment or food supplement for sleep disorders within the last month before screening;
• Volunteer presenting current infection and/or fever;
• Volunteer with medical history of stroke or head trauma;
• Pregnant or lactating woman;
• Known allergy or intolerance to one product component (valerian, eschscholtzia or excipients);
• Subjects having participated to another clinical trial (with an investigational product) one month before the inclusion;
• Subjects that present alterations of their cognitive functions that will interfere with the comprehension of the study and procedures and/or with the completion of questionnaires;
• Vulnerable patient (deprived of liberty by judicial or administrative decision, under guardianship, curatorship or safeguard of justice, …);
• Pharmacological resistance to common hypnotic/sedative drugs;
• Allergy/intolerance to the actimeter straps;
• Recent (< 1 month before the inclusion) change in lifestyle (food, body weight > 5kg, sport).